Microbot Medical (MBOT) Stock Sees Fair Value Cut As Liberty Adoption Outlook Softens

Microbot Medical Inc. SEC Filing (Nov 3, 2026)

Microbot Medical (NasdaqCM:MBOT) Stock Forecast & Analyst Predictions

Microbot Medical® Secures its First Office-Based Lab (OBL) Customer for the LIBERTY® Endovascular Robotic System

Microbot Medical Receives Order From ELMNT IR For 12-Month Supply Of Liberty Devices

Microbot Medical® Attending Key Medical Conference to Engage with Decision-makers as it Continues to Expand Presence Across the U.S.

Citizens Initiates Coverage On Microbot Medical with Market Outperform Rating, Announces Price Target of $2.5

HC Wainwright & Co. Reiterates Buy on Microbot Medical, Maintains $12 Price Target

Microbot Medical® Granted Multiple New Patents, Further Strengthening Its Global Intellectual Property Portfolio

Microbot Medical Receives Several New Patent Approvals Across US, Japan, China And Canada, Further Strengthening Its Global IP Portfolio

Microbot Medical® and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in Israel

Microbot Medical Inks Three-Year Distribution Deal With Medtechnica To Advertise, Sell LIBERTY System In Israel

Microbot Medical® Highlights Growth Strategy

Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates

Microbot Medical® Among Featured Companies Showcasing Novel Robotic Technologies and Digital Surgery Applications at the Society of Robotic Surgery Annual Meeting